Shots:

• Tmunity & University of California enter into an exclusive research agreement for the improvement of TCR therapies for rare diseases including DIPG in pediatric patients. Tmunity will be responsible for development & commercialization of the H3.3K27M TCR therapy
• The focus of the collaboration is to strengthen Tmunity’s portfolio by developing therapies for diffuse intrinsic pontine glioma (DIPG) targeting H3.3K27M i.e- K27M mutation in the H3.3 histone
• Tmunity’s portfolio includes T cell therapy platforms- T cell receptors- regulatory T cells- gene transfer- allogeneic T cells and bionic T cells & CAR-T programs used for activating or suppressing immunity

Ref: Tmunity | Image: Pinterest